Primary Cesarean Section in Primigravida and Muligravida in Sohag and Al Balyana Cities

October 9, 2023 updated by: Sahar Nasser Fathy, Sohag University
cesarean section and vaginal delivery are two methods of delivery, cesarean section somtimes indicated for obstetrical reason but primary cesarean section especially in primigravida might have a preference of the mode of delivery

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Salah M Rasheed, professor
  • Phone Number: 01224653702

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

all primigravida with gestational age more than 28 weeks and above who have come for delivery

  • multigravida upto gravida 4 with gestational age more than 28 weeks and above who has had one previous viable vaginal delivery
  • women between 18 and 45 years

Description

Inclusion Criteria:

  • all primigravida with gestational age more than 28 weeks and above who have come for delivery
  • multigravida upto gravida 4 with gestational age more than 28 weeks and above who has had one previous viable vaginal delivery
  • women between 18 and 45 years

Exclusion Criteria:

  • primigravida women <28 weeks
  • multigravida <28 weeks
  • patient having previous history of myomectomy or hystrotomy
  • gravida 5 and more

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
primigravida
Other: rate of cesarean section
rate of primary cesarean section in primigravida and multigravida
multigravida
Other: rate of cesarean section
rate of primary cesarean section in primigravida and multigravida

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
rate
Time Frame: 6 months
rate of primary cesarean section
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 24, 2023

Primary Completion (Estimated)

March 24, 2024

Study Completion (Estimated)

March 24, 2024

Study Registration Dates

First Submitted

October 9, 2023

First Submitted That Met QC Criteria

October 9, 2023

First Posted (Actual)

October 16, 2023

Study Record Updates

Last Update Posted (Actual)

October 16, 2023

Last Update Submitted That Met QC Criteria

October 9, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • Soh-Med-23-09-03MS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe